Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1085 - Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases

Date

10 Sep 2017

Session

Poster display session

Topics

Clinical Research;  Prostate Cancer

Presenters

Nobuaki Matsubara

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

N. Matsubara1, Y. Naito1, M. Sasaki2, N. Yamamoto3, S. Takahashi4, H. Uemura5, T. Doi6

Author affiliations

  • 1 Department Of Breast And Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Department Of Medical Oncology, Kyoundo Hospital, 101-0062 - Tokyo/JP
  • 3 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Department Of Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo/JP
  • 5 Department Of Urology/renal Transplantation, Yokohama City University Medical Center, 232-0024 - Yokohama/JP
  • 6 Department Of Experimental Therapeutics, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
More

Resources

Abstract 1085

Background

TAS-115 is a novel small-molecule inhibitor of hepatocyte growth factor receptor (MET) and vascular endothelial growth factor receptor (VEGFR) with antitumor activity in preclinical models. It has also been shown that TAS-115 inhibits Feline McDonough Sarcoma oncogene (FMS) kinase, essential for the differentiation of osteoclasts, and is expected to be effective against bone metastases. In this expansion cohort of phase I trial, the safety and efficacy of TAS-115 were evaluated in CRPC pts with bone metastases.

Methods

Eligible CRPC pts with bone metastases who were refractory to standard treatment including docetaxel, abiraterone and/or enzalutamide were enrolled. Two dose levels of TAS-115 (450 and 650 mg/body/day) were administered orally with a 5-days-on/2-days-off schedule for up to 21 days per cycle in this expansion cohort. Efficacy was evaluated based on the RECIST ver 1.1 and bone scan response, defined as 30% decrease in bone scan index (BSI) calculated by quantitative software of BONENAVI®(FUJIFILM RI Pharma, Japan; EXINI bone®, Exini Diagnostics, Sweden). Toxicities were evaluated based on the CTCAE ver 4.03.

Results

As of Apr 2017, a total of 15 pts received TAS-115 (9 pts with 450 mg, and 6 pts with 650 mg). Bone scan response was reported in 4 of 9 pts (44.4%) who had baseline BSI ≥0.5%, which is equivalent to grade≥1 extent of disease. The best overall response per RECIST was stable disease in 7 of 15 pts (46.7%). These efficacies were observed regardless to dose levels. One patient had a long administration period exceeded to 15 months without disease progression, and another one patient experienced remarkable pain relief induced by bone metastases. TAS-115 had no effect on the PSA and ALP. The major (≥30%) adverse drug reactions (ADRs) were anorexia, fatigue, nausea, thrombocytopenia, rash, AST increased, anemia, vomiting and edema. The rate of grade ≥3 to all ADRs was 18.8%. These AEs were recovering by interruption of TAS-115.

Conclusions

Toxicities of TAS-115 were acceptable and manageable in CRPC pts, and preliminary anti-tumor activity, especially against bone metastases was recognized. A phase II trial for CRPC pts with bone metastases is ongoing.

Clinical trial identification

JapicCTI-132333/163448

Legal entity responsible for the study

Taiho Phermaceutical CO., LTD.

Funding

Taiho Phermaceutical CO., LTD.

Disclosure

N. Matsubara: Honoraria: Taiho Pharmaceutical. Consulting or Advisory role: Janssen, AstraZeneca. Speakers’ bureau: Janssen, AstraZeneca, Sanofi. Research funding: Janssen, Bayer. Y. Naito: Speakers’ bureau: Eisai, Chugai, Taiho, Novartis, Eli Lilly, Meiji Seika, Bayer, Roche. Research Funding: Merck Serono, AstraZeneca, Eli Lilly, Nippon Kayaku. M. Sasaki: Speakers’ bureau: Taiho. Research funding: Eisai, Bayer. N. Yamamoto: Honoraria: AstraZeneca, Pfizer, Chugai, Bristol-Myers, Ono, Eli Lilly. Research funding: Chugai, Taiho, Eisai, Quintiles, Astellas, Novartis, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, Takeda, Kyowa Hakko, Bayer, Pfizer. S. Takahashi: Honoraria: Eisai, Astellas, Taiho, Bayer, Daiichi, Pfizer, AstraZeneca, Merck, Sanofi, Novartis, Ono, Bristol, MSD. Consulting or Advisory role: Chugai, Astellas, Bayer, Pfizer. Research funding: Eisai, Chugai, MSD, Lilly, AstraZeneca, Novartis, Taiho, Bayer, Astellas, Ono, Daiichi. H. Uemura: Consulting or Advisory role: Janssen, Takeda. Speakers' bureau: Janssen, Takeda, Astellas, Bayer, Sanofi, AstraZeneca, Fujifilm. Research funding: Astellas. T. Doi: Consulting or Advisory Role: Lilly, Chugai, Kyowa Hakko Kirin, Novartis, MSD, Daiichi Sankyo, Amgen. Research funding: Taiho, Merck, Astellas, Janssen, Takeda, Pfizer, Lilly, Sumitomo Group, Bayer, Chugai, Kyowa Hakko Kirin, Boehringer, Novartis, MSD, Daiichi Sankyo, Celgene.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.